Company Information

FRESENIUS KABI ONCOLOGY LTD.

NSE : NABSE : 532545ISIN CODE : INE575G01010Industry : Pharmaceuticals & DrugsHouse : Fresenius Kabi Oncology - MNC
BSE132.450 (0 %)
PREV CLOSE ( ) 132.45
OPEN PRICE ( ) 132.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 132.45 (20430)
VOLUME 91518
TODAY'S LOW / HIGH ( )132.00 132.60
52 WK LOW / HIGH ( ) 132132.6
NSE
This Company is not listed in NSE
ChairmanMaria Gobbi
Managing DirectorArvind Kumar Sharma
Non Executive DirectorMichael Schoenhofen
Steffen Georg Roser
Karsten Peter Lerch
Rakesh Bhargava
Non Executive Independent DirectorRajiv Lochan Jain
Uday Chandrashekhar Shetty
Whole Time DirectorNikhil Kulshreshtha
Incorporation Year : 18-03 2003

Registered Office :

Address : B - 310,Som Datt Chambers - I,Bhikaji Cama Place New Delhi,
Delhi-110066 .

Phone : 011-26105570

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.